Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 13
---
 reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. Accordingly,
and as described in the Letter, unless we timely requested a hearing before a Hearings Panel, or the Panel, our securities would be subject
to suspension/delisting. We requested a hearing, which automatically stayed any suspension or delisting action pending the hearing and
the expiration of any additional extension period granted by the Panel following the hearing.

On October 14, 2024, the Panel
granted our request for an extension of time to demonstrate compliance with the Minimum Bid Price Requirement. On November 7, 2024, we
were formally notified that the Hearings Panel determined that we had regained compliance with the Minimum Bid Price Requirement. We remain
subject to a discretionary panel monitor through February 24, 2025, and we are required to provide prompt notification during this exception
period of any significant events that occur during this time that may affect our compliance with NASDAQ requirements.

Depositary Share Ratio Change and Change in Nominal Value

On October 4, 2024, and in
an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 400 Ordinary Shares per Depositary Share to
10,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On November 22, 2024, we held
the November GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of £0.001 nominal value each into
one ordinary share of £0.00005 nominal value and 19 C Deferred Shares of £0.00005 nominal value each, which became effective
on November 25, 2024 and (y) adopt new Articles of Association, which make consequential amendments to the existing articles of association
of the Company to reflect the November Subdivision. As is standard for deferred shares, each C Deferred Share has very limited rights
and is effectively valueless. The C Deferred Shares have the rights and restrictions as set out in the Articles of Association and do
not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend
or other distribution.

Registered Direct Offering and Concurrent Private Placement

On
July 22, 2024, we completed the closing of a registered direct offering, or the